Effect of Exogenous Melatonin Administration in Critically Ill Patients on Delirium and Sleep: A Randomized Controlled Trial

Table 4

Sleep analysis in study groups.

	Group A	Group B	P
	N = 21	N = 12
	Melatonin	Placebo
	Median (IQR)	Median (IQR)
Hrs studied from 7pm, baseline	10 (10–10)	10 (10–10)	0.80
Hrs studied from 7pm, drug	10 (10–10)	10 (10–10)	0.57
Arousal index
Baseline	8.95 (6.6–20.3)	7.6 (6.6–20.3)	0.80
Posttreatment	12.9 (8.4–24.4)	15.7 (1.8–66)	0.81
Sleep stages	N = 14	N = 8
Stage 1 (%)
Baseline	0.26 (0.00–1.00)	0 (0.0–1.7)	0.37
Posttreatment	2.17 (0.75–3.25)	0.25 (0.0–2.03)	0.10
Change from baseline to posttreatment	0.89 (−0.33–2.42)	0.17 (−0.04–0.60)	0.39
Stage 2 (%)
Baseline	24.67 (6.93–40.08)	2.92 (0.17–15.75)	0.02
Posttreatment	21.17 (15.57–43.15)	16.30 (6.35–31.25)	0.13
Change from baseline to posttreatment	−3.49 (−9.27–15.83)	9.35 (1.56–27.18)	0.25
Stage 3 (%)
Baseline	11.67 (5.23–54.81)	7.00 (0.50–83.33)	0.94
Posttreatment	16.50 (1.92–29.33)	54.58 (11.05–59.52)	0.02
Change from baseline to posttreatment	17.54 (1.92–29.33)	46.03 (10.3–58.17)	0.08
REM (%)
Baseline	0 (0–0.08)	0 (0–0)	0.32
Posttreatment	1.05 (0–4.42)	0 (0–0)	0.05
Change from baseline to posttreatment	0.13 (0–1.5)	0 (0–0)	0.35
Awake (%)
Baseline	32.50 (13.07–58.5)	69.08 (13.86–96)	0.62
Posttreatment	45.69 (34.02–70.67)	21.29 (3.50–61.63)	0.22
Change baseline to posttreatment	8.34 (−13.17–15.42)	−11.56 (−47.10–3.93)	0.22